Companies / BOC Sciences / Nirsevimab
BOC Sciences

Nirsevimab | BOC Sciences

(0) Write Review

Nirsevimab is a monoclonal antibody developed for the prevention of respiratory syncytial virus (RSV) infections in infants. Nirsevimab specifically targets the respiratory syncytial virus (RSV) fusion (F) protein, which is essential for viral entry and replication in respiratory cells. By binding to the F protein, nirsevimab prevents RSV from infecting cells and replicating, thereby reducing the likelihood of severe respiratory illness. It is being investigated for the prevention of RSV infection in infants, particularly those at high risk of severe disease. RSV is a common respiratory virus that can cause serious illness, especially in premature infants and those with certain medical conditions.

Reviews

(0) | Be the first to review this product
No reviews yet

ABOUT THE COMPANY

BOC Sciences
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
Scientific Products
  • See More
    • Upcoming Virtual Events
    Upcoming Webinars